Shamim Ruff - Sarepta Therapeutics President
| SRPT Stock | USD 126.66 2.14 1.66% |
President
Ms. Shamim Ruff is Senior Vice President, Chief Regulatory Affairs Officer of the Company. Prior to this appointment, she served as our Vice President, Regulatory Affairs and Quality since January 2013. From April 2011 to December 2012, Ms. Ruff served as Vice President, Regulatory Affairs at Sanofi, a pharmaceutical company, where she was Head of Oncology Regulatory Affairs, responsible for leading Global, European, and CMC Regulatory Affairs teams. Prior to working at Sanofi, Ms. Ruff served as Executive Director, US and Global Regulatory Affairs at Amgen from March 2007 to March 2011. She previously held senior positions at Abbott and AstraZeneca, where she had global oversight for the development and filings of multiple compounds, some of which had companion diagnostics since 2016.
| Age | 57 |
| Tenure | 8 years |
| Address | 215 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0524) % which means that it has lost $0.0524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8615) %, meaning that it created substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39 M in 2024.Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Greg Zante | Viking Therapeutics | N/A | |
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
| Suma Krishnan | Krystal Biotech | 59 | |
| Catherine Kelleher | Viking Therapeutics | N/A | |
| Amy Broidrick | Viking Therapeutics | N/A | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Gregory Zante | Viking Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Kaye, Senior Vice President Chief Medical Officer | ||
| Alexander Cumbo, Vice President Head of Commercial | ||
| William Ciambrone, Ex Operations | ||
| Dallan Murray, Executive Officer | ||
| Hans Wigzell, Independent Director | ||
| Michael Bonney, Director | ||
| Sandesh Mahatme, CFO, Chief Accounting Officer and Sr. VP | ||
| Ryan JD, General VP | ||
| Jayant Aphale, Senior Vice President - Technical Operations | ||
| Mary Gray, Director | ||
| Douglas Esq, CEO President | ||
| Anthony Chase, Independent Director | ||
| Douglas Ingram, President CEO | ||
| Gilmore ONeill, Senior Vice President Chief Medical Officer | ||
| JeanPaul Kress, Director | ||
| Joan Wood, Vice President - Human Resources | ||
| Alison Nasisi, Executive Officer | ||
| Bilal Arif, Executive Officer | ||
| Ryan Brown, Gen VP | ||
| Richard Barry, Independent Director | ||
| Gil Price, Independent Director | ||
| Catherine StehmanBreen, Senior Vice President Chief Medical Officer | ||
| David Howton, Sr. VP, General Counsel and Corporate Secretary | ||
| Mary Jenkins, Sr Relations | ||
| Ian Estepan, Executive CFO | ||
| Guriqbal Basi, Senior Vice President Chief Scientific Officer | ||
| Will Tilton, Head VP | ||
| William Goolsbee, Non-Executive Independent Chairman of the Board | ||
| Louise RodinoKlapac, Chief VP | ||
| Claude Nicaise, Independent Director | ||
| Kathleen Behrens, Independent Director | ||
| Diane Berry, Executive Officer | ||
| Erin Cox, IR Contact | ||
| Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality | ||
| Francesca Nolan, Executive Communications |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 11.81 B | ||||
| Shares Outstanding | 94.51 M | ||||
| Shares Owned By Insiders | 4.39 % | ||||
| Shares Owned By Institutions | 86.90 % | ||||
| Number Of Shares Shorted | 4.87 M | ||||
| Price To Earning | (20.43) X |
Currently Active Assets on Macroaxis
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.80) | Revenue Per Share 13.456 | Quarterly Revenue Growth 0.535 | Return On Assets (0.05) | Return On Equity (0.86) |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.